Last updated: March 8, 2026
What is the product associated with NDC 73473-0903?
The National Drug Code (NDC) 73473-0903 corresponds to Ombitasvir, Paritaprevir, Ritonavir and Dasabuvir combination therapy. It is primarily used for treating chronic hepatitis C virus (HCV) infection, genotypes 1 and 4.
Market Overview
Indications and Competitive Landscape
The drug addresses HCV genotype 1 and 4 infections, competing in a highly saturated market with direct-acting antivirals (DAAs). Major competitors include Gilead Sciences’ Harvoni (ledipasvir/sofosbuvir) and Epclusa (sofosbuvir/velpatasvir), as well as AbbVie's Viekira Pak and Vosevi.
Market Size and Penetration
The global HCV treatment market was valued at approximately USD 4.7 billion in 2020 (IQVIA), with a projected compound annual growth rate (CAGR) of 7% through 2028 driven by increased screening and expanded access. The United States accounts for 55% of sales, with Europe and Asia-Pacific capturing the remainder.
Price Trends and Cost Dynamics
DAA prices have decreased since launch, driven by patent expirations, increased competition, and biosimilar entry in some regions. The average wholesale price (AWP) for combination therapies has declined roughly 20-30% over the past three years.
Price Projections
Current Pricing (2023)
- Average Wholesale Price (AWP): USD 45,000 – USD 65,000 per treatment course
- Average Selling Price (ASP): Approximate USD 35,000 – USD 50,000, varying by region
- Reimbursement landscape: Insurers and government programs often negotiate discounts, reducing actual transaction prices.
Short-term Projections (Next 2 Years)
Prices are expected to decrease further as patents approach expiry and biosimilar products emerge:
| Year |
Estimated Price Range |
Drivers |
| 2023 |
USD 40,000 – USD 55,000 |
Continued generic competition and cost containment |
| 2024 |
USD 35,000 – USD 50,000 |
Patent expiration negotiations, more biosimilars entering the market |
| 2025 |
USD 30,000 – USD 45,000 |
Increased biosimilar penetration, preferential formulary placements |
Long-term Projections (Next 5 Years)
Beyond 2025, competitive pricing and global access efforts could reduce treatment costs further:
| Year |
Estimated Price Range |
Drivers |
| 2026-2028 |
USD 25,000 – USD 40,000 |
Market saturation, biosimilar proliferation, pricing pressures |
Influencing Factors
- Patent expiration: Expected in 2024 for some formulations, opening pathways for biosimilars.
- Regulatory approvals: Speed of biosimilar approval in key markets determines price decline rate.
- Market penetration: Adoption rates influenced by insurance coverage and physician prescribing habits.
- Manufacturing costs: Technology improvements could reduce production expenses and prices.
Key Market Dynamics
- Reimbursement: Varies significantly by region. In the US, Medicaid, Medicare, and commercial plans negotiate discounts.
- Pricing strategies: Manufacturers may offer discounts, rebates, and patient assistance programs to maintain market share amid declining list prices.
- Generic/Biosimilar Entry: Biosimilars are anticipated to enter the US market around 2024-2025, exerting additional downward pressure on prices.
Potential Risks
- Regulatory delays: Slower approval or reimbursement restrictions could impact sales and prices.
- Market saturation: High cure rates reduce long-term demand.
- Patent litigation: Ongoing disputes may prolong patent protections and keep prices high.
Conclusion
The NDC 73473-0903 product, a combination HCV therapy, faces declining prices driven by patent expirations and increased biosimilar availability. Short-term prices likely remain in the USD 40,000 – USD 55,000 range, with further reductions over the next five years potentially lowering treatment costs by 50% from current levels in competitive markets.
Key Takeaways
- The HCV treatment market is mature, with prices trending downward due to competition.
- Prices are expected to decline by approximately 20-30% over the next two years.
- Biosimilars could reduce prices further, reaching USD 25,000 – USD 40,000 per treatment course by 2028.
- Reimbursement policies and regulatory pathways significantly influence actual transaction prices.
- The market’s saturation and high cure rates limit long-term revenue growth.
FAQs
-
When will biosimilars for this drug likely enter the market?
Biosimilars are anticipated to gain approval around 2024-2025, depending on regional regulatory processes.
-
Are there existing generic options for this combination?
Currently, no generics exist; biosimilars are on the horizon and expected to impact pricing substantially.
-
How do regional policies affect prices?
European countries often negotiate lower prices via national health systems, whereas the US relies heavily on rebates and negotiations with private insurers.
-
What factors could accelerate price declines?
Faster biosimilar approvals, increased market competition, and broader global access initiatives.
-
How has the COVID-19 pandemic impacted the HCV treatment market?
The pandemic temporarily slowed healthcare access and prescription volumes but has not significantly altered long-term price trends.
Citations
[1] IQVIA. (2021). Global hepatitis C market analysis.
[2] SSR Health. (2023). Average drug pricing and discounts.
[3] FDA. (2022). Biosimilar approval timelines.
[4] Centers for Medicare & Medicaid Services. (2023). Reimbursement policies for hepatitis C therapies.
[5] European Medicines Agency. (2023). Biosimilar approval process and market entry timelines.
